Prolonged Survival in Peritoneal Metastatic Appendiceal Carcinoma Patients Treated With Combined Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:2
|
作者
Acs, Miklos [1 ,5 ]
Gerken, Michael [2 ]
Zustin, Jozef [3 ,4 ]
Blaj, Sebastian [1 ]
Isgandarova, Sabina [1 ]
Piso, Pompiliu [1 ]
机构
[1] Hosp Barmherzige Bru, Dept Gen & Visceral Surg, Regensburg, Germany
[2] Univ Regensburg, Inst Qual Management & Hlth Serv Res, Tumor Ctr, Regensburg, Germany
[3] Univ Med Ctr Muenster, Gerhard Domagk Inst Pathol, Munster, Germany
[4] Inst Pathol Regensburg, Regensburg, Germany
[5] Hosp Barmherzige Bru, Dept Gen & Visceral Surg, Prufeninger Str 86, D-93049 Regensburg, Germany
关键词
Appendix carcinoma; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastases; LYMPH-NODE METASTASIS; SIGNET-RING CELLS; PSEUDOMYXOMA PERITONEI; MUCINOUS ADENOCARCINOMA; NEOPLASMS; CLASSIFICATION; DISSEMINATION; DIAGNOSIS; FEATURES; OUTCOMES;
D O I
10.1016/j.jss.2022.10.083
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Primary treatment for peritoneal dissemination of appendiceal cancer is the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The endpoints were overall survival and evaluation of prognostic factors.Methods: Clinicopathological and treatment-related factors were obtained from a pro-spective database. A total of 84 patients, 55 (65%) primary and 29 (35%) recurrent malignant appendiceal carcinomas with synchronous and metachronous peritoneal metastases, underwent multimodal treatment between 2011 and 2021. The endpoints of the study were overall survival and evaluation of prognostic factors.Results: The median follow-up was 4.8 y; the mean age was 54.5 y (range 25-77), with a sex distribution of 69% female and 31% male. The mean peritoneal cancer index was 11.3. The proportion of mucinous, intestinal-type, signet ring cell, and goblet cell carcinoma was 56%, 23%, 11%, and 10%, respectively. The 5-y survival rate of the whole cohort was 56.7%. In primary and recurrent diseases, the overall median survival was 8.4 and 4.9 y. Signifi-cantly improved survival was detected after complete cytoreduction resection (hazard ratio [HR] for CCR-2 versus CCR-0: 9.388, 95% confidence interval [CI] 3.026-29.124, P = 0.001) and initial local operation with undelayed admission to the center (HR 0.262, 95% CI 0.089-0.773; P = 0.015). The five independent factors in Kaplan-Meier analysis and univariable Cox regression analysis associated with significant adverse survival were cancer antigen (CA) 19-9 over 37 IU/mL, signet ring cell and intestinal-type histology, positive nodal status, grading, and peritoneal cancer index >20. Neoadjuvant chemotherapy administration did not impact survival (HR 1.220, 95% CI 0.612-2.432, P = 0.571).Conclusions: With multimodal treatment, prolonged survival is attainable in stage IV pri-mary and recurrent appendiceal carcinoma with peritoneal dissemination. Direct referral to specialized centers after confirmation of peritoneal metastasis is recommended because prompt definitive treatment may significantly improve survival.& COPY; 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:839 / 852
页数:14
相关论文
共 50 条
  • [1] Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Blackham, Aaron U.
    Swett, Katrina
    Eng, Cathy
    Sirintrapun, Joseph
    Bergman, Simon
    Geisinger, Kim R.
    Votanopoulos, Konstantinos
    Stewart, John H.
    Shen, Perry
    Levine, Edward A.
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (07) : 740 - 745
  • [2] Predictive and Prognostic Survival Factors in Peritoneal Carcinomatosis from Appendiceal Cancer After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Jimenez, William
    Sardi, Armando
    Nieroda, Carol
    Sittig, Michelle
    Milovanov, Vladimir
    Nunez, Maria
    Aydin, Nail
    Gushchin, Vadim
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (13) : 4218 - 4225
  • [3] Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: Analysis of survival outcomes
    Sardi, A.
    Jimenez, W. A.
    Nieroda, C.
    Sittig, M.
    MacDonald, R.
    Gushchin, V.
    EJSO, 2013, 39 (11): : 1207 - 1213
  • [4] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours
    Ansari, N.
    Chandrakumaran, K.
    Dayal, S.
    Mohamed, F.
    Cecil, T. D.
    Moran, B. J.
    EJSO, 2016, 42 (07): : 1035 - 1041
  • [5] Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA)
    Milovanov, V.
    Sardi, A.
    Ledakis, P.
    Aydin, N.
    Nieroda, C.
    Sittig, M.
    Nunez, M.
    Gushchin, V.
    EJSO, 2015, 41 (05): : 707 - 712
  • [6] Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma
    Flood, Michael P.
    Roberts, Georgia
    Mitchell, Catherine
    Ramsay, Robert
    Michael, Michael
    Heriot, Alexander G.
    Kong, Joseph C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (01) : 32 - 40
  • [7] Impact of signet ring cells on overall survival in peritoneal disseminated appendix cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Shamavonian, Raphael
    Lansom, Joshua D.
    Karpes, Josh B.
    Alzahrani, Nayef A.
    Morris, David L.
    EJSO, 2021, 47 (01): : 194 - 198
  • [8] Peritoneal metastases from adrenal cortical carcinoma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Sugarbaker, Paul H.
    TUMORI, 2016, 102 (06) : 588 - 592
  • [9] A Prognostic Model for Predicting Overall Survival in Patients with Peritoneal Surface Malignancy of an Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Ihemelandu, Chukwuemeka
    Fernandez, Stephen
    Sugarbaker, Paul H.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (08) : 2266 - 2272
  • [10] Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Gaillard, M.
    Van Eyken, P.
    Verswijvel, G.
    van der Speeten, K.
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2023, 14 (SUPPL 1) : 240 - 249